Key result
Initiation of phosphodiesterase-5 inhibitors is not associated with the risk of incident Alzheimer's disease and related dementia.
Why the study?
Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer's disease and related dementias?
Key points are not available for this paper at this time.
Design
Editorial
This commentary discusses a study finding no association between phosphodiesterase-5 inhibitors and incident Alzheimer's disease.
No takes yet. Share an insight, caveat, or question.
Danielle Newby (2022) studied this question. Initiation of phosphodiesterase-5 inhibitors is not associated with the risk of incident Alzheimer's disease and related dementia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: